硼替佐米方案与常规方案治疗多发性骨髓瘤的临床研究

Clinical study of bortezomib and conventional regimens for multiple myeloma

目的对比硼替佐米为主的化疗方案与常规化疗方案治疗多发性骨髓瘤的疗效。方法选取我院血液内科2015~2018年收治的44例初发多发性骨髓瘤患者为研究对象,分为对照组(21例,采用常规化疗方案治疗)和试验组(23例,采用以硼替佐米为主的化疗方案治疗),对比两组治疗效果。结果试验组治疗总缓解率(95.65%)较对照组(80.95%)高,差异具有统计学意义(P<0.05);试验组患者较对照组患者在贫血和体能评分的改善以及骨痛缓解等方面比化疗前差异具有明显的统计学意义(P<0.05);试验组除了心脏毒性的发生率低于对照组以外,其他不良反应发生率和总不良反应率均高于对照组。结论硼替佐米为主的化疗方案在改善多发性骨髓瘤患者贫血发生速率、体能评分和骨痛明显优于常规化疗方案,但不良反应发生率高。

Objective To compare the efficacy of bortezomib-based chemotherapy and conventional chemotherapy in the treatment of multiple myeloma.Methods Forty-four patients with multiple myeloma who were treated in our hospital from 2015 to 2018 were selected as the research subjects and divided into the control group(21 cases,treated with conventional chemotherapy)and the experimental group(23 cases,treated with bortezomib-based chemotherapy regimen),the treatment effects of the two groups were compared.Results The total remission rate(95.65%)in the experimental group was higher than that in the control group(80.95%),and the difference was statistically significant(P<0.05).The patients in the experimental group had improved anemia and physical fitness scores,and alleviated bone pain.The difference was statistically significant compared with that before chemotherapy(P<0.05);except for the incidence of cardiotoxicity in the experimental group,which was lower than that in the control group,the incidence of adverse reactions in other parts and the total adverse reaction rate were higher than those in the control group.Conclusion The bortezomib-based chemotherapy regimen is significantly better than conventional chemotherapy regimens in improving anemia rates,fitness scores,and bone pain in patients with multiple myeloma,but with a higher incidence of adverse reactions.